Načítá se...
Double Biologic Therapy for Refractory Stricturing Crohn’s Disease: A Successful Case of Deep Remission with Ustekinumab and Vedolizumab
Stricturing Crohn’s disease (CD) is a severe phenotype that presents unique challenges to therapeutic management. Emerging literature suggests that anti-TNF monoclonal antibody (mAb) therapies are inadequate for preventing progression to stricture. We hereby present a case of a patient with refracto...
Uloženo v:
| Vydáno v: | Inflamm Bowel Dis |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Oxford University Press
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7301404/ https://ncbi.nlm.nih.gov/pubmed/32386054 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ibd/izaa092 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|